Skip to main content

Table 1 Results in the MITT populations of pivotal trials of echinocandins for therapy of invasive fungal infections [45, 5557]

From: Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature

  Anidulafungin Caspofungin Micafungin
Comparator Fluconazole Amphotericin B deoxycholate Liposomal amphotericin B Caspofungin ****
Patient number (MITT), n 127 / 118 109 / 115 247 / 247 191 / 188
Candidemia, % 91 / 87 82.6 / 79.1 84.2 / 85.8 *** 85.3 / 85.6
Infection with C. non -albicans, % 36 / 41 * 64.4 / 45.9
[p = 0.0009]
62.4 / 58.9 *** 54.5 / 60.6
Neutropenia, % 2.4 / 3.4 12.8 / 8.7 11.9 / 7.9 *** 11.5 / 5.9
Switched to oral fluconazole, % 26.0 / 28.0 24.8 / 34.8 Not allowed 20.9 / 21.2
Global success at end of IV therapy, % 75.6 / 60.2
[p = 0.01]
73.4 / 61.7
[p = n.s.]
74.1 / 69.6
p = n.s.]
76.4 / 72.3
p = n.s.]
Global success at end of all therapy, % 74.0 / 56.8
[p < 0.02]
72.5 / 61.7
[p = n.s.]
74.1 / 69.6
[p = n.s.]
74.9 / 70.2
[p = n.s.]
Global success at 2 weeks follow up, % 64.6 / 49.2
[p < 0.02]
63.6 / 53.8
[p = n.s.]
Not reported 54.5/ 50.5
[p = n.s.]
Global success at 6 weeks follow up, % 55.9 / 44.1
[p = n.s.]
56.6 /47.5 **
[p = n.s.]
Not reported 46.6 / 42.6
[p = n.s.]
Microbiological success at end of IV therapy, % 88.1 / 76.2 Not reported Not reported 88.5 / 84.0
Time to negative blood cultures, days 2 / 5
(C. albicans)[59]
Not reported 3 / 4 *** 2 / 2
Persistent infection, % 6.3 / 14.4
[p = n.s.]
8.3 / 8.7
[p = n.s.]
8.9 / 8.4 ***
[p = n.s.]
5.8 / 9.6
[p = n.s.]
Mortality rate (ITT), % 22.8 / 31.4
[p = n.s.]
34.2 / 30.4
[p = n.s.]
40 / 40
[p = n.s.]
29.0 / 26.4
  1. * Patients with C. krusei infection were excluded from the trial.
  2. ** Follow-up at 6-8 weeks after end of all therapy.
  3. *** In the per-protocol set.
  4. **** Column excludes results of micafungin 150 mg arm.